Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD (PAP-OCD)

This open-label clinical trial (n=10) evaluates the feasibility, clinical effects, and safety of psilocybin-assisted psychotherapy (25mg, 2x) for treatment-resistant obsessive-compulsive disorder (OCD).

Participants, aged 18 to 65, diagnosed with treatment-resistant OCD, will receive two doses of 25mg of psilocybin, two weeks apart, alongside supportive therapy.

The study aims to recruit and retain participants with TROCD and assess the safety of psilocybin-assisted psychotherapy, measured by adverse events and the Columbia Suicide Severity Rating Scale. Additionally, the trial will measure changes in OCD symptoms using the Yale-Brown Obsessive Compulsive Scale (YBOCS) and evaluate secondary outcomes such as treatment response, depression severity, and quality of life.

The study is conducted by the Centre for Addiction and Mental Health (CAMH) and will run from April 2024 to September 2024.

Topic Obsessive-Compulsive Disorder Depression Safety
Compound Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.